查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511820

美国外分泌胰臟功能不全诊断市场规模、份额和趋势分析报告：按诊断方法、最终用途和细分市场预测，2024-2030 年

U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Method (Laboratory Tests, Imaging Tests), By End-use (Hospitals, Clinics, Diagnostic Laboratories), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 85 Pages | 商品交期: 2-10个工作天内

价格

美国外分泌胰臟功能不全诊断市场的成长与趋势

Grand View Research最新报告显示，到2030年，美国外分泌胰臟功能不全诊断的市场规模预计将达到23.9亿美元，2024年至2030年复合年增长率为7.04%。

有几个因素正在推动市场成长，例如胰臟疾病盛行率的增加、技术进步以及有利的政府倡议和资金。该行业未来的一个关键趋势是将机器学习演算法和人工智慧 (AI) 与诊断工具整合。例如，胃肠病学人工智慧平台等基于人工智慧的软体平台可以分析来自电脑断层扫描和 MRI 的医学影像资料，以帮助医疗专业人员更准确、更有效地识别胰臟功能不全的征兆。此类技术趋势预计将在未来提高诊断准确性、减少解释错误并改善患者治疗结果，从而推动预测期内的产品需求。

随着市场竞争变得更加激烈，消费者对改进的高产量、可靠的诊断设备和耗材的需求从未如此强烈。 电脑断层扫描和 MRI 中的人工智慧等新时代技术预计将扰乱传统产品的销售，并在市场上开闢新的研发机会。价格、相容性、安全性和获得结果的时间是区分新 EPI 测试技术与现有 EPI 测试技术的关键因素，从而赋予它们竞争优势。例如，ALPCO Diagnostics 推出了最先进的测试，包括胰臟弹性蛋白酶 (PE)化学冷光ELISA 和 CLIA 测试，旨在快速准确地检测粪便中的胰臟弹性蛋白酶。这些先进的检测方法为医疗保健专业人员提供了诊断 EPI 的可靠方法，有助于快速介入并改善患者的治疗结果。然而，公司正专注于开发功效更高、成本更低的新产品。

美国胰臟外分泌功能不全诊断市场报告亮点

  • 根据诊断方法，实验室检测产业在 2023 年占据了最大的收益占有率。实验室检查包括间接胰臟功能检查和其他检查，如胰臟炎基因检测（如遗传性胰臟炎基因组）和13C混合三酸甘油酯呼吸检测，以诊断患者的外分泌胰臟功能不全。
  • 另一方面，包括血液检测和粪便检验在内的间接胰臟功能检测领域预计在预测期内将以显着的复合年增长率成长。
  • 根据最终用途，医院和诊所部门在 2023 年占据最大的收益占有率。
  • 全国范围内强大的医院和诊所网络以及拥有熟练诊断严重 EPI 的工作人员是医院和诊所成为诊断和治疗首选的主要因素。
  • 市场的併购活动处于低至中等水平，显示竞争格局稳定，注重内部发展而非外部整合。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国外分泌胰臟功能不全诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国胰臟外分泌功能不全诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 监管场景
  • 退款场景
  • 价格分析
  • 目标人口分析

第四章美国外分泌胰臟功能不全诊断市场：诊断方法的估计与趋势分析

  • 美国外分泌胰臟功能不全诊断市场：诊断方法细分仪表板
  • 美国外分泌胰臟功能不全诊断市场：诊断方法变化分析
  • 2018-2030年美国胰臟外分泌功能不全诊断市场规模及趋势分析（依诊断方法）
  • 临床检查
  • 影像检查

第五章美国外分泌胰臟功能不全诊断市场：依最终用途分类的估计与趋势分析

  • 美国外分泌胰臟功能不全诊断市场：最终用途细分仪表板
  • 美国外分泌胰臟功能不全诊断市场：最终用途变异分析
  • 2018-2030年美国外分泌胰臟功能不全诊断市场规模与趋势分析（依最终用途）
  • 医院/诊所
  • 诊断实验室
  • 研究机构

第六章 竞争状况

  • 参与企业分类
  • 参与企业概况
  • 财务绩效
  • 产品基准
  • 热图分析
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 消费行为分析
    • ChiRhoClin
    • Certest Biotec.
    • ScheBo Biotech AG
    • Immundiagnostik AG
    • Laboratory Corporation of America Holdings
    • Boster Biological Technology
    • ALPCO Diagnostics
    • Quest Diagnostics Incorporated
    • DiaSorin SpA
    • ARUP Laboratories
    • Alpha Laboratories
    • Verisana Laboratories
Product Code: GVR-4-68040-299-1

U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Growth & Trends:

The U.S. exocrine pancreatic insufficiency diagnostics market size is expected to reach USD 2.39 billion by 2030, growing at a CAGR of 7.04% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are driving market growth, including increasing incidence of pancreatic diseases, technological advancements, and favorable government initiatives & funding. A key future trend in the industry is the integration of machine learning algorithms and Artificial Intelligence (AI) with diagnostic tools. For instance, AI-based software platforms like the gastroenterology-AI platform analyze medical imaging data from CT scans or MRIs to assist healthcare professionals in identifying signs of pancreatic insufficiency more accurately and efficiently. This technological trend is expected to enhance diagnostic accuracy, reduce interpretation errors, and improve patient outcomes in the future, thereby driving the demand for products over the forecast period.

As the market becomes increasingly competitive, consumer needs are at an all-time high for improved diagnostic instruments and consumables in terms of high yield & robust outcomes. New-age technologies, such as AI in CT scans and MRIs, are expected to impede the sales of older products, opening new R&D opportunities in the market. Price, compatibility, safety, and time taken to provide results are major factors differentiating new EPI testing technologies from existing ones, thereby gaining a competitive edge over them. For instance, ALPCO Diagnostics introduces state-of-the-art assays, including the Pancreatic Elastase (PE) Chemiluminescence ELISA and CLIA tests, designed to detect pancreatic elastase rapidly & accurately in the stool. These advanced assays offer healthcare professionals a reliable means of diagnosing EPI, facilitating prompt intervention and improved patient outcomes. However, companies are focusing on developing newer products with higher efficacy made available at lower costs.

U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Report Highlights:

  • Based on diagnostic method, the laboratory tests segment accounted for the largest revenue share in 2023. Laboratory tests include indirect pancreatic function tests and other tests such as genetic testing for pancreatitis (such as Hereditary Pancreatitis Gene Panel) and 13C-mixed triglyceride breath tests for diagnosing exocrine pancreatic insufficiency in patients.
  • On the other hand, the indirect pancreatic function test segment, which includes blood tests and stool tests, is expected to grow at a significant CAGR during the forecast period.
  • Based on end-use, the hospitals and clinics segment accounted for the largest revenue share in 2023.
  • The presence of a strong network of hospitals & clinics throughout the country and the availability of skilled staff for diagnosing severe EPI are some of the key factors responsible for the high preference of hospitals & clinics for diagnosis and treatment.
  • The market is characterized by a low-to-moderate level of merger and acquisition activity, indicating a landscape characterized by stable competition and a focus on internal development rather than external consolidation.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Diagnostic Method
    • 1.2.2. End-use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Diagnostic Method Outlook
    • 2.2.2. End-use Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target disease
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Growing awareness and screening initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory hurdles and compliance requirements
      • 3.2.2.2. Underdiagnosis and misdiagnosis
  • 3.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Regulatory Scenario
  • 3.5. Reimbursement Scenario
  • 3.6. Pricing Analysis
  • 3.7. Target Population Analysis

Chapter 4. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Estimates & Trend Analysis

  • 4.1. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Segment Dashboard
  • 4.2. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Movement Analysis
  • 4.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size & Trend Analysis, by Diagnostic Method, 2018 to 2030 (USD Million)
  • 4.4. Laboratory Tests
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Indirect Pancreatic Function Tests
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Stool Tests
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Blood Tests
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Tests
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Imaging Tests
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. CT Scans
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. MRI
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Endoscopic Ultrasound for Pancreatic Function Tests
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Segment Dashboard
  • 5.2. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Movement Analysis
  • 5.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals & Clinics
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Diagnostic Laboratories
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Research Institutes
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant Categorization
  • 6.2. Participant Overview
  • 6.3. Financial Performance
  • 6.4. Product Benchmarking
  • 6.5. Heat Map Analysis
  • 6.6. Vendor Landscape
    • 6.6.1. List of key distributors and channel partners
    • 6.6.2. Consumer behavior analysis
    • 6.6.3. ChiRhoClin
      • 6.6.3.1. Company overview
      • 6.6.3.2. Financial performance
      • 6.6.3.3. Product benchmarking
      • 6.6.3.4. Strategic initiatives
    • 6.6.4. Certest Biotec.
      • 6.6.4.1. Company overview
      • 6.6.4.2. Financial performance
      • 6.6.4.3. Product benchmarking
      • 6.6.4.4. Strategic initiatives
    • 6.6.5. ScheBo Biotech AG
      • 6.6.5.1. Company overview
      • 6.6.5.2. Financial performance
      • 6.6.5.3. Product benchmarking
      • 6.6.5.4. Strategic initiatives
    • 6.6.6. Immundiagnostik AG
      • 6.6.6.1. Company overview
      • 6.6.6.2. Financial performance
      • 6.6.6.3. Product benchmarking
      • 6.6.6.4. Strategic initiatives
    • 6.6.7. Laboratory Corporation of America Holdings
      • 6.6.7.1. Company overview
      • 6.6.7.2. Financial performance
      • 6.6.7.3. Product benchmarking
      • 6.6.7.4. Strategic initiatives
    • 6.6.8. Boster Biological Technology
      • 6.6.8.1. Company overview
      • 6.6.8.2. Financial performance
      • 6.6.8.3. Product benchmarking
      • 6.6.8.4. Strategic initiatives
    • 6.6.9. ALPCO Diagnostics
      • 6.6.9.1. Company overview
      • 6.6.9.2. Financial performance
      • 6.6.9.3. Product benchmarking
      • 6.6.9.4. Strategic initiatives
    • 6.6.10. Quest Diagnostics Incorporated
      • 6.6.10.1. Company overview
      • 6.6.10.2. Financial performance
      • 6.6.10.3. Product benchmarking
      • 6.6.10.4. Strategic initiatives
    • 6.6.11. DiaSorin S.p.A.
      • 6.6.11.1. Company overview
      • 6.6.11.2. Financial performance
      • 6.6.11.3. Product benchmarking
      • 6.6.11.4. Strategic initiatives
    • 6.6.12. ARUP Laboratories
      • 6.6.12.1. Company overview
      • 6.6.12.2. Financial performance
      • 6.6.12.3. Product benchmarking
      • 6.6.12.4. Strategic initiatives
    • 6.6.13. Alpha Laboratories
      • 6.6.13.1. Company overview
      • 6.6.13.2. Financial performance
      • 6.6.13.3. Product benchmarking
      • 6.6.13.4. Strategic initiatives
    • 6.6.14. Verisana Laboratories
      • 6.6.14.1. Company overview
      • 6.6.14.2. Financial performance
      • 6.6.14.3. Product benchmarking
      • 6.6.14.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 U.S. Exocrine Pancreatic Insufficiency Diagnostics market revenue estimates and forecast, by Diagnostic Method, 2018 - 2030 (USD Million)
  • Table 4 U.S. exocrine pancreatic insufficiency diagnostics market revenue estimates and forecast, by end-use, 2018 - 2030 (USD Million)
  • Table 5 Laboratory information U.S.
  • Table 6 List of players adopting merger & acquisition strategy
  • Table 7 List of players adopting acquisition strategy
  • Table 8 List of players adopting other strategy

List of Figures

  • Fig. 1 U.S. exocrine pancreatic insufficiency diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment.
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Diagnostic method and end-use segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Market dynamics
  • Fig. 12 Porter's five forces analysis
  • Fig. 13 PESTLE analysis
  • Fig. 14 U.S. Exocrine Pancreatic Insufficiency Diagnostics market: Diagnostic Method outlook and key takeaways
  • Fig. 15 U.S. Exocrine Pancreatic Insufficiency Diagnostics market: Diagnostic Method movement analysis
  • Fig. 16 Laboratory Tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Laboratory Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 18 Indirect Pancreatic Function Tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Indirect Pancreatic Function Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 20 Stool Tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Stool Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 22 Blood Tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Blood Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 24 Other tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 26 Imaging tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Imaging tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 28 CT scans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 CT scans market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 30 MRI market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Endoscopic ultrasound for pancreatic function tests for pancreatic function tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Endoscopic ultrasound for pancreatic function tests for pancreatic function tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 33 U.S. exocrine pancreatic insufficiency diagnostics market: By end-use, key takeaways
  • Fig. 34 U.S. exocrine pancreatic insufficiency diagnostics market, by end-use: Market share, 2023 & 2030
  • Fig. 35 Hospitals and clinics market, 2018 - 2030 (USD Million)
  • Fig. 36 Diagnostic laboratories market, 2018 - 2030 (USD Million)
  • Fig. 37 Research institutes market, 2018 - 2030 (USD Million)
  • Fig. 38 Research institutes market, 2018 - 2030 (Number of Tests, '000)
  • Fig. 39 Company/competition categorization
  • Fig. 40 Heat map analysis
  • Fig. 41 Consumer behavior analysis
  • Fig. 42 Exocrine pancreatic insufficiency diagnostics industry key takeaways
  • Fig. 43 Strategy mapping